ArticleJournal of immunology research2018
Naturally Derived Anti-HIV Polysaccharide Peptide (PSP) Triggers a Toll-Like Receptor 4-Dependent Antiviral Immune Response.
Article in Journal of immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Resolution-Phase Immunometabolic Reprogramming byMarine drugs · 2026Article
- Medicinal Mushrooms and Their Bioactive Compounds: From Traditional Use to Therapeutic Potential.Molecules (Basel, Switzerland) · 2026Review
- Time- and Dose-Dependent PSP-Induced Modulation of Antiviral Signaling Networks in CD4+ T Cells.International journal of molecular sciences · 2026Article
- Molecular Regulation of HIV-1 Expression and Persistence Across Diverse Cellular Reservoirs.International journal of molecular sciences · 2026Review
- Review
- Research Progress of Polysaccharide-Gold Nanocomplexes in Drug Delivery.Pharmaceutics · 2024Review
- Oncogenic Proteomics Approaches for Translational Research and HIV-Associated Malignancy Mechanisms.Proteomes · 2023Review
- The Antiviral Compound PSP Inhibits HIV-1 Entry via PKR-Dependent Activation in Monocytic Cells.Viruses · 2023Article
- COVID-19 and Cancer Diseases-The Potential ofInternational journal of molecular sciences · 2023Review
- Medicinal Fungi with Antiviral Effect.Molecules (Basel, Switzerland) · 2022Review
- Can food matrices be considered as a potential carrier for COVID-19?Le infezioni in medicina · 2022Review
- Bioactives from Mushroom: Health Attributes and Food Industry Applications.Materials (Basel, Switzerland) · 2021Review
- Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials.International journal of molecular sciences · 2021Review
- Food Ingredients and Active Compounds against the Coronavirus Disease (COVID-19) Pandemic: A Comprehensive Review.Foods (Basel, Switzerland) · 2020Review
- Anti-feline immunodeficiency virus reverse transcriptase properties of some medicinal and edible mushrooms.Veterinary world · 2020Article
- Article
- Anti-viral activity of culinary and medicinal mushroom extracts against dengue virus serotype 2: an in-vitro study.BMC complementary and alternative medicine · 2019Article
- New targets for HIV drug discovery.Drug discovery today · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
aimIntense interest remains in the identification of compounds to reduce human immunodeficiency virus type 1 (HIV-1) replication. MATERIALS AND
methodsHIV-1 p24 and anti-HIV chemokine release was assessed in HIV-positive (HIV+) THP1 cells and validated in HIV+ peripheral blood mononuclear cells (PBMCs), to determine PSP antiviral activity. The involvement of TLR4 activation in PSP anti-HIV activity was evaluated by inhibition.
resultsPSP showed a promising potential as an anti-HIV agent, by downregulating viral replication and promoting the upregulation of specific antiviral chemokines (RANTES, MIP-1
conclusionTaken together, these findings put forward the first evidence that PSP exerts an anti-HIV activity mediated by TLR4 and key antiviral chemokines. Elucidating these new molecular mediators may reveal additional drug targets and open novel therapeutic avenues for HIV-1 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.